$87.22 Million in Sales Expected for Imperva Inc (IMPV) This Quarter

Analysts expect Imperva Inc (NASDAQ:IMPV) to report $87.22 million in sales for the current quarter, according to Zacks. Nine analysts have issued estimates for Imperva’s earnings, with the lowest sales estimate coming in at $86.70 million and the highest estimate coming in at $88.00 million. Imperva posted sales of $74.44 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 17.2%. The business is scheduled to announce its next earnings report on Thursday, July 26th.

On average, analysts expect that Imperva will report full-year sales of $371.49 million for the current year, with estimates ranging from $368.00 million to $374.20 million. For the next fiscal year, analysts anticipate that the company will post sales of $425.55 million per share, with estimates ranging from $414.00 million to $431.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Imperva.

Imperva (NASDAQ:IMPV) last posted its earnings results on Thursday, April 26th. The software maker reported $0.26 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.07. Imperva had a negative net margin of 3.00% and a negative return on equity of 1.63%. The firm had revenue of $84.24 million during the quarter, compared to analysts’ expectations of $83.77 million. During the same period last year, the company posted $0.09 EPS. The company’s quarterly revenue was up 16.5% compared to the same quarter last year.

A number of analysts have weighed in on the stock. BidaskClub upgraded shares of Imperva from a “hold” rating to a “buy” rating in a research note on Tuesday, April 17th. ValuEngine raised shares of Imperva from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Stephens raised their price objective on shares of Imperva from $61.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, June 14th. BTIG Research reissued a “hold” rating on shares of Imperva in a report on Sunday, April 29th. Finally, Oppenheimer raised their price objective on shares of Imperva from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, June 18th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $53.42.

A number of large investors have recently modified their holdings of IMPV. Schwab Charles Investment Management Inc. lifted its holdings in Imperva by 12.6% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 156,057 shares of the software maker’s stock valued at $6,196,000 after purchasing an additional 17,453 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in Imperva during the fourth quarter valued at approximately $394,000. Sei Investments Co. lifted its holdings in Imperva by 196,449.0% during the fourth quarter. Sei Investments Co. now owns 96,309 shares of the software maker’s stock valued at $3,824,000 after purchasing an additional 96,260 shares in the last quarter. UBS Asset Management Americas Inc. lifted its holdings in Imperva by 21.4% during the fourth quarter. UBS Asset Management Americas Inc. now owns 15,301 shares of the software maker’s stock valued at $607,000 after purchasing an additional 2,700 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new position in Imperva during the fourth quarter valued at approximately $224,000.

Shares of Imperva stock traded up $0.20 during trading on Monday, hitting $48.25. The company’s stock had a trading volume of 334,707 shares, compared to its average volume of 282,022. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -172.32 and a beta of 1.69. Imperva has a 52 week low of $37.17 and a 52 week high of $53.95.

Imperva Company Profile

Imperva, Inc engages in the development, market, sale, and support of cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. The company's SecureSphere product line provides database, file, and Web application security in various data centers, including on-premises data centers, as well as in private, public, and hybrid cloud computing environments.

Get a free copy of the Zacks research report on Imperva (IMPV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply